The 12 companies selected will work alongside Mayo Clinic Platform's experts and leverage its de-identified clinical data ecosystem to advance digital health solution development. The program aims to transform healthcare through AI-enabled solutions leveraging clinical data and advanced analytics.
A new AI-assisted approach uses artificial intelligence to help novice users capture heart images and identify patients with aortic stenosis. The approach, presented in a study published in JAMA Cardiology, enables novice users to collect focused heart ultrasound images and analyze them for signs of moderate or greater aortic stenosis,...
Researchers discovered 5 subtypes of liver disease, each with unique risks for heart disease, liver failure, and cancer. The study, published in Nature Communications, used genetic sequencing and clinical data to define distinct subtypes of metabolic dysfunction-associated steatotic liver disease.
The Lancet Haematology series examines how clinicians can better identify and track treatment effects on patients during and after blood cancer treatment. Digital tools, such as symptom-reporting apps and artificial intelligence, could support changes in care, but must be accurate and equitable.
Scientists have identified a microbiome signaling system that controls intestinal movement, revealing a potential new direction for treating constipation-predominant irritable bowel syndrome. The discovery points to restoring combinations of microbial signals to restore normal function.
Mayo Clinic joins a consortium to develop affordable, scalable gene-editing therapies for children with rare inherited immune disorders. Researchers will use CRISPR-based technologies to repair disease-causing errors in blood-forming stem cells.
Researchers estimated cancer risk in patients with pancreatic cysts with worrisome or high-risk features, finding that risk increased with the number of worrisome features. The study suggests that regular surveillance may be an appropriate approach for some patients rather than immediate surgery.
The AI model, developed by Mayo Clinic researchers, can identify patients with left ventricular outflow tract obstruction from routine ultrasound videos without relying on specialized Doppler imaging. This technology could help clinicians flag patients with hypertrophic cardiomyopathy who may need additional testing, particularly in se...
Researchers developed an experimental drug using AI to target a 'undruggable' protein in pancreatic cancer, slowing tumor growth and improving survival rates. The study demonstrates the potential for AI-assisted discovery of new cancer treatments.
A Mayo Clinic study highlights the benefits of animal-assisted treatment in stroke rehabilitation, showing increased patient engagement and improved rehabilitation outcomes. Therapy animals support patients with limited motivation, reduced energy and lack of companionship.
Researchers discovered a protein called TRAILshort that suppresses T-cell activity and reduces the effectiveness of CAR-T cell therapy in cancer patients. Elevated levels of TRAILshort were found in various cancers, infectious diseases, and autoimmune disorders.
The collaboration enables researchers and innovators to develop, validate, and scale AI-enabled solutions across a broader representation of patient populations. This global health data network, called Mayo Clinic Platform_Connect, includes eight members and spans seven countries across three continents.
Researchers identify a previously unknown mechanism linking dysfunctional mitochondria and epigenetic machinery to chronic inflammation in aging cells. The discovery reveals how senescent cells drive inflammation by switching on inflammatory genes through metabolic signals from mitochondria.
Researchers develop SenMayo gene set to identify senescent cells across different tissues and experimental models. Several studies evaluate approaches to reduce the burden or harmful effects of senescent cells in preclinical models.
A new immunotherapy treatment has been shown to be effective in treating high-risk bladder cancer, allowing many patients to keep their bladder instead of having it surgically removed. The treatment, called cretostimogene grenadenorepvec, produced a complete response in 75% of patients, with most side effects being mild and temporary.
A Mayo Clinic study found that bringing clinical trial activities directly to patients can increase participation among rural and underserved communities. The decentralized program expanded access to research, increasing enrollment from 16.6% to 24.9% in rural communities and 12.5% to 17.4% among underserved racial and ethnic populations.
Researchers identified a distinct biological subtype of obesity that responds well to GLP-1-based medications like tirzepatide. Patients in this group lost an average of 21.5% of their body weight after six months of treatment.
A Mayo Clinic-led study found that continuing maintenance therapy beyond two years did not improve overall survival for patients with standard-risk multiple myeloma. The findings suggest that treatment duration can be safely tailored, reducing treatment burden and costs.
Researchers have validated a genetic scoring tool that can identify patients with idiopathic pulmonary fibrosis and predict clinical outcomes. The tool, which combines the effects of over 60,000 DNA variants, shows promise in distinguishing the disease from other forms of interstitial lung disease.
A new Mayo Clinic study shows that integrating telomere length evaluation and genetic testing into pulmonary care can significantly change how physicians diagnose and treat pulmonary fibrosis. Nearly 1 in 5 patients had a disease-causing genetic variant, leading to changes in clinical care for more than half of patients.
Researchers created a detailed map of the pulvinar, a deep brain region that could help doctors precisely target brain stimulation therapies for people with drug-resistant epilepsy. The study reveals that brain regions separated by only a few millimeters connect to entirely different brain networks.
Researchers found that patients who received tranexamic acid during liver surgery were three times less likely to develop post-hepatectomy liver failure than those who received a placebo. The study suggests targeting the body's fibrinolytic system may support liver regeneration and reduce liver failure risk.
Mayo Clinic researchers have identified a previously hidden step in the immune system's preparation to fight cancer, suggesting that the thymus plays a crucial role in training T cells before they enter circulation. This discovery could lead to more effective and longer-lasting cancer immunotherapies.
Mayo Clinic researchers have discovered the molecular structure of protein kinase C beta (PKCβ), a key protein linked to cancer and neurological diseases. The findings provide a promising target for developing more precise therapies for these conditions, including breast cancer and Alzheimer's disease.
Researchers have identified a previously unrecognized way the kidneys regulate water balance, which could lead to improved treatments for polycystic kidney disease. The discovery reveals an alternative mechanism that operates independently of the hormone vasopressin.
Researchers mapped individual cell genetic footprints to understand tumor behavior, identifying distinct immune cell states linked to disease aggressiveness and patient outcomes. The study aims to refine treatment decisions and develop noninvasive biomarkers for monitoring patients.
Researchers used tissue samples, pathology images, and clinical data from 672 patients to train AI models to classify meningioma subtypes and predict recurrence risk. The findings suggest that AI can help clinicians obtain more detailed tumor information without requiring advanced genetic testing.
A new proactive treatment protocol, PACT, combines medication and frequent follow-up to prevent alcohol relapse after liver transplant. Researchers found a 0% heavy alcohol relapse rate among patients who followed the protocol, compared to a historical rate of approximately 25%.
The collaboration aims to expand access to Mayo Clinic's knowledge and integrated model of care, using advanced AI capabilities to support earlier diagnoses, personalized treatment decisions, and better patient outcomes. The frontier AI model will be owned by Mayo Clinic and made available through Microsoft Azure Foundry APIs.
A recent study found that hormone therapy use among US women has steadily declined from 4.4% in 2007 to 1.7% in 2023, despite its proven benefits for symptom relief and quality of life. The majority of women who could benefit from hormone therapy are not receiving it due to misconceptions about risks and limited training among clinicians.
Researchers will present over 30 studies on precision oncology, early cancer detection and AI-powered personalized care. Featured topics include biomarker-driven treatments for bladder and lung cancers, new approaches for triple-negative breast cancer and AI-enabled analysis of tumor microenvironment in colon cancer.
A new Mayo Clinic study sequenced the genomes of 484 healthy adults, finding that 13% carried a serious genomic risk. The study highlights the challenges of integrating genomic findings into routine care and positions predictive genomic screening as a clinical opportunity.
Researchers identified ST8Sia6, an immune-regulating molecule, as a potential explanation for treatment-resistant IBD. The study found that the absence of ST8Sia6 led to increased inflammation in preclinical models.
Dr. Gianrico Farrugia will complete his tenure as Mayo Clinic President and CEO in December, leaving a legacy of strategic advancement and innovation. The institution has accelerated disease cures, connected people with data, and transformed healthcare through its AI-enabled care transformation platform.
The study identifies nine distinct cellular neighborhoods in the tumor microenvironment, each associated with survival and immunotherapy response outcomes. The blood-based liquid biopsy test could guide treatment decisions for multiple cancer types and treatments.
A study published in JHLT Open found that remote patient monitoring can detect early health changes and support care decisions for lung transplant recipients. The system generated nearly 470 alerts, with most prompting changes in care, such as clinic visits or medication adjustments.
The Mayo Clinic AI model detects pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis, identifying subtle signs of disease. The model identified 73% of prediagnostic cancers at a median of about 16 months before diagnosis.
A new study from Mayo Clinic suggests that Alzheimer's disease may start as early as the late 50s, with subtle biological changes accelerating over time. Researchers analyzed data from 2,082 participants and found that biomarkers of tau pathology and neurodegeneration show more pronounced increases around ages 68 to 72.
A Mayo Clinic study found that bariatric surgery reduces long-term cardiovascular risk more effectively than weight-loss medications. The study analyzed outcomes for 812 adults with obesity and found that greater weight loss led to larger reductions in lifetime cardiovascular risk.
Researchers at Mayo Clinic have developed a blood-based method to detect germ cell tumors, the most common type of testicular cancer, including cases that do not show up on standard blood tests. The new test, GCT-iSIGN, identified 93% of individuals with germ cell tumors and correctly ruled out cancer in 99% of those without.
Researchers treated seven patients with advanced heart disease and difficult-to-treat ventricular tachycardia. The therapy resulted in a 79% reduction in VT episodes, with no serious treatment-related side effects during follow-up of up to two years. Proton beam therapy offers a new approach for patients with limited treatment options.
A Mayo Clinic study provides preclinical evidence for a targeted approach to managing immune-related kidney inflammation triggered by immunotherapy. The findings suggest that TNF-alpha blockade may improve markers of kidney injury and could be explored as a preventive measure.
Rosa Rademakers' groundbreaking discovery of the C9orf72 hexanucleotide repeat expansion revealed a common genetic origin for ALS and frontotemporal dementia, transforming how scientists study and diagnose these conditions.
Researchers at Mayo Clinic have developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, improving survival rates in preclinical models of glioblastoma. The approach uses small lipid-based particles to target tumor cells and enhance the impact of radiation therapy.
A new technique identifies proteins that trigger strong immune responses, challenging a common assumption in the field. The ratio of immunogenicity measurement reveals patterns among hundreds of proteins, highlighting mitochondrial proteins as particularly immunogenic.
A new study published in Mayo Clinic Proceedings found that robotic bronchoscopy has a high sensitivity for malignancy (85%) and accuracy rate (76.9%), with a complication rate of 2.8%. The technology allowed for earlier detection of lung cancer, reducing diagnoses at advanced stages from 54% to 31%, and improved survival rates.
A Mayo Clinic study found that AI-derived heart fat measurement can predict cardiovascular events more accurately when combined with traditional risk assessment approaches. The measurement significantly improved long-term risk prediction, especially among patients at low-risk categories.
Researchers at Mayo Clinic found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer reduced cancer recurrence and mortality by 50% compared to chemotherapy alone. The study used an immune checkpoint inhibitor, atezolizumab, to reactivate a person's anti-tumor immunity.
A Mayo Clinic study found that wearable sleep data can improve the prediction of patient engagement in a 12-week home pulmonary rehabilitation program. By combining baseline sleep data with machine learning and traditional clinical indicators, clinicians can tailor more effective care plans for patients with COPD.
Researchers found that vitamin D supplementation was associated with increased levels of immunoglobulin A and decreased levels of immunoglobulin G, indicating a more balanced immune response. The study also observed changes in immune signaling pathways and increased activity of regulatory immune cells.